Urat1 inhibitor, pharmaceutical compositions and uses thereof
US-2024226070-A1 · Jul 11, 2024 · US
US10066025B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10066025-B2 |
| Application number | US-201314414734-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 16, 2013 |
| Priority date | Jul 16, 2012 |
| Publication date | Sep 4, 2018 |
| Grant date | Sep 4, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention described herein relates to the discovery that renalase, and fragments thereof, are useful for the treatment or prevention of cardiac and renal diseases or disorders. Thus, the invention relates to compositions comprising renalase, or fragments thereof, and methods for treating and preventing cardiac and renal disease or disorders.
Opening claim text (preview).
The invention claimed is: 1. A composition comprising a polypeptide comprising at least one amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 2, and the amino acid sequence of SEQ ID NO: 4.
Antihypertensives · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Antineoplastic agents · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.